• Crescendo links with CRUK to progress cancer therapy pharmatimes
    May 06, 2020
    Crescendo Biologics and Cancer Research UK have entered into a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.
PharmaSources Customer Service